1. Search Result
Search Result
Results for "

TNFRSF4/OX40/CD134

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

7

Inhibitory Antibodies

14

Recombinant Proteins

6

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990559

    TNF Receptor Inflammation/Immunology
    BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    BMS-986178
  • HY-P991338

    Orexin Receptor (OX Receptor) Cancer
    MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
    MEDI-6469
  • HY-P991339

    Orexin Receptor (OX Receptor) Cancer
    ZL-1101 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134.
    ZL-1101
  • HY-P991334

    Orexin Receptor (OX Receptor) Cancer
    INCAGN1949 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. INCAGN1949 selectively deplete intratumoral regulatory T cells .
    INCAGN1949
  • HY-P990678

    TNF Receptor Inflammation/Immunology
    Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Vonlerizumab
  • HY-P992141

    BAT6026

    Orexin Receptor (OX Receptor) TNF Receptor Others
    Vedastotug is a human monoclonal antibody targeting TNFRSF4/OX40/CD134, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .
    Vedastotug
  • HY-P992368

    TNF Receptor Cancer
    HLX51 is a regulatory T cell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatory T cell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector T cell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and T cell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas .
    HLX51

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: